Work

Precision Oncology Tumor Board—a new series to facilitate a global dialogue

Year: 2019

Type: article

Abstract: Over the last two decades since the first breakthrough discoveries, such as the use of imatinib for chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) sarcomas and trastuzumab for ErbB2-positive breast cancers there has been an explosion of knowledge as to our understanding of the molecular genetics of malignancies (1-3).

Source: Precision Cancer Medicine

DOI: 10.21037/pcm.2019.07.01

Author: Balazs Halmos

Institutions: Albert Einstein College of Medicine, Montefiore Medical Center

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W2965246978

FWCI:

Cites:

Cited by: 1

Related to: 10